Having trouble accessing articles? Reset your cache.

Synovir thalidomide data

CELG announced that pivotal Phase II/III testing has reached the primary end point, change in body weight, after eight weeks of therapy. Preliminary results, presented

Read the full 253 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE